CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...